SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a poster at the 2020 American Society of Human Genetics (ASHG) Annual Meeting, which is being held in a virtual format this year due to COVID-19.
Presentation details are as follows:
Poster Title: A robust imaging and single-cell sequencing platform to characterize tumor extrachromosomal DNA (ecDNA) in response to therapeutic intervention
Session: 202 - Cancer
Poster #: 2251
Date: October 26, 2020
Time: 6:00 a.m. – 11:59 p.m. ET
About ecDNA
Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes. ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies and can be passed to daughter cells asymmetrically during cell division, driving tumor heterogeneity. Cancer cells have the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells’ primary mechanisms of recurrence and treatment resistance. ecDNA are rarely seen in healthy cells but are found in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
About Boundless Bio
Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.
